Semaglutide was associated with more than twice the risk for nonarteritic anterior ischemic optic neuropathy compared with SGLT2 inhibitors, although the absolute risk “remained low,” according to a ...
Monthly Prescribing Reference: Semaglutide Doubles Risk for Nonarteritic Anterior Ischemic Optic Neuropathy
Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay News — ...
GLP-1 receptor agonists (RA) may increase the risk of non-arteritic anterior ischemic optic neuropathy (NAION), although the absolute risk is low. Studies supporting the association have reported ...
Patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) appear to have a very low incidence of nonarteritic anterior ischemic optic neuropathy (NAION) when appropriately prescribed ...
Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with type 2 ...
A novel gene therapy that leads to cellular rejuvenation could restore vision after non-arteritic anterior ischemic optic neuropathy (NAION) and glaucoma. The technique is based on a reprogramming ...
Anterior ischemic optic neuropathy (AION) occurs when there is not enough blood flow into the eye. This causes damage to the optic nerve, quickly leading to vision loss. There are two subtypes of AION ...
The Cardiology Advisor: Semaglutide Linked to Increased Risk for Ischemic Optic Neuropathy
Researchers evaluated potential associations between semaglutide exposure and ischemic optic neuropathy across various formulations and patient subgroups.
Medscape: Risk for Ischemic Optic Neuropathy From Glucagon-Like Peptide 1 Receptor Agonists Too Rare to be Detected